Journal of Breast Cancer · 2021 · 11 citations · 22 references
MedicineImmunologyOncologyBreast OncologyCancer ImmunologyTumor ImmunologyCancer BiomarkersCancer Survival AnalysisImmuno-oncology BiomarkersNeutrophil BiologyDisease-free Survival AnalysisDisease-free Survival AssessmentImmune Biomarker ProfilingKaplan-meier Confidence IntervalsNeutrophil-to-lymphocyte RatioPrognostic ModelsPrognostic PredictionTriple-negative Breast Cancer Therapy
PURPOSE: Triple-negative breast cancer (TNBC) has been associated with worse prognosis, and biomarkers are needed to identify high-risk patients who may benefit from clinical trials or escalated treatment after completion of standard treatment. We aimed to assess whether the post-treatment neutrophil-to-lymphocyte ratio (NLR) can reflect patient prognosis and determine the follow-up period that can provide the most feasible data. METHODS: In this retrospective analysis involving patients with TNBC, clinicopathological data, including those on peripheral complete blood cell count, were collected. The prognostic powers of serial NLRs obtained at baseline and after treatment completion were compared. Kaplan-Meier curves were generated to compare the overall survival (OS) and distant disease-free survival (DDFS). RESULTS: < 0.001) than low NLR group. CONCLUSION: Elevated post-treatment NLR was significantly associated with worse survival in patients with TNBC. We believe that it can be a useful surrogate marker for identifying high-risk patients with TNBC.
22
M. Elizabeth H. Hammond, Daniel F. Hayes, Mitch Dowsett et al. · Journal of Clinical Oncology · 2010 · 4.3K citations · Full text
Medicine, Cancer Biology, Oncology +14
Antonio C. Wolff, M. Elizabeth Hammond, David G. Hicks et al. · Journal of Clinical Oncology · 2013 · 4.1K citations · Full text
Pembrolizumab for Early Triple-Negative Breast Cancer
Peter Schmid, Javier Cortés, Lajos Pusztai et al. · New England Journal of Medicine · 2020 · 3.1K citations · Full text
Medicine, Oncology, Pharmacotherapy +16
Christina Davies, Hongchao Pan, Jon Godwin et al. · The Lancet · 2012 · 2K citations · Full text
Medicine, Endocrinology, Oncology +14
Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy
Norikazu Masuda, Soo-Jung Lee, Shoichiro Ohtani et al. · New England Journal of Medicine · 2017 · 1.9K citations · Full text
Medicine, Oncology, Pharmacotherapy +17